AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23212996 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier quintiles of modified Alternative Healthy Eating Index scores
Number of subjects: 31546
Study 23212996 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier diet
Number of subjects: 31546
Study 19763805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic facial expressions
Number of subjects: 13
Study 19763805 — intervention group
Group type: COMPARATOR
Intervention: Static facial expressions
Number of subjects: 13
Study 19097474 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger movement before gait initiation
Number of subjects: 13
Study 19097474 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger movement after gait initiation
Number of subjects: 13
Study 19097474 — intervention group
Group type: COMPARATOR
Intervention: No finger movement (gait initiation without finger movement)
Number of subjects: 13
Study 17136691 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (60 mg) mixed with human albumin (HA)
Number of subjects: 0
Study 17136691 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (60 mg) mixed with fresh frozen plasma (FFP)
Number of subjects: 0
Study 17136691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 0
Study 14572020 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention trial
Number of subjects: 23125
Study 14572020 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition
Number of subjects: 23125
Study 14572020 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 23125
Study 10799416 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation during pregnancy
Number of subjects: 5
Study 15321272 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 0
Study 15321272 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 0
Study 8244521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.7 mmol/kg)
Number of subjects: 24
Study 8244521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium chloride (2.2 mmol/kg)
Number of subjects: 24
Study 8244521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2428885 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (CGRP)
Number of subjects: 0
Study 2428885 — intervention group
Group type: COMPARATOR
Intervention: Histamine, prostaglandin (PG) E2, PGI2, substance P, vasoactive intestinal peptide (VIP)
Number of subjects: 0
Study 30810347 — intervention group
Group type: EXPERIMENTAL
Intervention: DR/ER-MPH 20 mg
Number of subjects: 62
Study 30810347 — intervention group
Group type: EXPERIMENTAL
Intervention: DR/ER-MPH 100 mg
Number of subjects: 62
Study 30810347 — intervention group
Group type: EXPERIMENTAL
Intervention: DR/ER-MPH 100 mg with high-fat meal
Number of subjects: 62
Study 30810347 — intervention group
Group type: EXPERIMENTAL
Intervention: DR/ER-MPH 100 mg sprinkled on applesauce
Number of subjects: 62
Study 30810347 — intervention group
Group type: EXPERIMENTAL
Intervention: DR/ER-MPH
Number of subjects: 62
Study 30810347 — intervention group
Group type: COMPARATOR
Intervention: IR MPH 20 mg
Number of subjects: 62
Study 30337510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (4 g/day for 72 postoperative hours)
Number of subjects: 140
Study 30337510 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 140
Study 27039845 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel/carboplatin + pelareorep (Arm A)
Number of subjects: 73
Study 27039845 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel/carboplatin (Arm B)
Number of subjects: 73
Study 25415108 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.5%) infusion at 2 ml/hour for 48 hours
Number of subjects: 80
Study 25415108 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 80
Study 22536662 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% H2O2 gel
Number of subjects: 15
Study 22536662 — intervention group
Group type: COMPARATOR
Intervention: 15% H2O2 gel
Number of subjects: 15
Study 22536662 — intervention group
Group type: EXPERIMENTAL
Intervention: Both concentrations of H2O2 gel with whitening lamp
Number of subjects: 15
Study 20644331 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day for 6 months
Number of subjects: 40
Study 17914513 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar dissection tonsillectomy
Number of subjects: 100
Study 17914513 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 100
Study 16044058 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine and felypressin (Citanest and Octapressin)
Number of subjects: 100
Study 16044058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12362927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 30 mg (three times a week)
Number of subjects: 68
Study 12362927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 60 mg (three times a week)
Number of subjects: 68
Study 12362927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 90 mg (single dose)
Number of subjects: 68
Study 12362927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 120 mg (single dose)
Number of subjects: 68
Study 12362927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 9925837 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal (GI) priming for 10 days
Number of subjects: 171
Study 9925837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus tube-feeding method
Number of subjects: 171
Study 9925837 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk feeding
Number of subjects: 171
Study 9925837 — intervention group
Group type: COMPARATOR
Intervention: Continuous tube-feeding method
Number of subjects: 171
Study 9925837 — intervention group
Group type: COMPARATOR
Intervention: GI priming
Number of subjects: 171
Study 7751894 — intervention group
Group type: EXPERIMENTAL
Intervention: 18FDG
Number of subjects: 16
Study 7751894 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C‐methionine
Number of subjects: 16
Study 7751894 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy
Number of subjects: 16
Study 2106735 — intervention group
Group type: EXPERIMENTAL
Intervention: multi‐dose blood cardioplegia (BCP)
Number of subjects: 37
Study 2106735 — intervention group
Group type: EXPERIMENTAL
Intervention: hypothermic ventricular fibrillation (HF)
Number of subjects: 37
Study 2106735 — intervention group
Group type: EXPERIMENTAL
Intervention: single‐dose Bretschneider's crystalloid cardioplegia (CCP)
Number of subjects: 37
Study 398481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor at a dose of 20 mg/kg/day
Number of subjects: 0
Study 398481 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor at identical dosages as phenoxymethyl penicillin
Number of subjects: 0
Study 398481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor administered twice daily or thrice daily
Number of subjects: 0
Study 398481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 0
Study 31549255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 184/22 mcg or 92/22 mcg
Number of subjects: 775900
Study 31549255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 775900
Study 31549255 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 775900
Study 30826974 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of Affect Recognition (TAR)
Number of subjects: 24
Study 30826974 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 24
Study 29714423 — intervention group
Group type: EXPERIMENTAL
Intervention: Yijingfang (half dose, bid) for 3 months
Number of subjects: 450
Study 29714423 — intervention group
Group type: COMPARATOR
Intervention: Wuziyanzong Pills (9 g, bid) + L‐carnitine oral liquid (10 ml, bid) for 3 months
Number of subjects: 450
Study 25469673 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS.NET (System for Individualized Survivorship Care)
Number of subjects: 102
Study 25469673 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 102
Study 22451455 — intervention group
Group type: COMPARATOR
Intervention: High Ligation and Stripping (HL/ST)
Number of subjects: 449
Study 22451455 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 449
Study 22451455 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation with High Ligation (EVLA/HL)
Number of subjects: 449
Study 21052638 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1‐84) (100 μg daily, subcutaneous injection)
Number of subjects: 81
Study 21052638 — intervention group
Group type: COMPARATOR
Intervention: Strontium ranelate (2 g daily, oral)
Number of subjects: 81
Study 21052638 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1‐84)
Number of subjects: 81
Study 19278378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 607
Study 19278378 — intervention group
Group type: COMPARATOR
Intervention: Traditional analgesics
Number of subjects: 607
Study 19278378 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 607
Study 16914234 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of pediatric inactivated HA vaccine (Avaxim 80) at 2, 4, and 6 months of age (Group A)
Number of subjects: 131
Study 16914234 — intervention group
Group type: COMPARATOR
Intervention: One dose of pediatric inactivated HA vaccine (Avaxim 80) at 6 months of age (Group B)
Number of subjects: 131
Study 12874818 — intervention group
Group type: EXPERIMENTAL
Intervention: Double filtration plasmapheresis (DFP)
Number of subjects: 8
Study 11203849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji‐II glass‐ionomer cement
Number of subjects: 0
Study 11203849 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgambond Plus
Number of subjects: 0
Study 11203849 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia‐21
Number of subjects: 0
Study 11203849 — intervention group
Group type: COMPARATOR
Intervention: Copalite
Number of subjects: 0
Study 11203849 — intervention group
Group type: COMPARATOR
Intervention: Prepared cavity without restoration
Number of subjects: 0
Study 9106107 — intervention group
Group type: EXPERIMENTAL
Intervention: High potassium supplementation (7.7 mmol/kg/day)
Number of subjects: 99
Study 9106107 — intervention group
Group type: COMPARATOR
Intervention: Standard potassium intake (4.7 mmol/kg/day)
Number of subjects: 99
Study 1443738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg)
Number of subjects: 9
Study 1443738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3001563 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ovine corticotropin releasing factor (oCRF) 25, 50, 100, 200 micrograms
Number of subjects: 6
Study 3001563 — intervention group
Group type: EXPERIMENTAL
Intervention: Human corticotropin releasing factor (hCRF) 50 and 100 micrograms
Number of subjects: 6
Study 3001563 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 6
Study 30806083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ameloblastoma (AM)
Number of subjects: 50
Study 30806083 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratocystic odontogenic tumor (KCOT)
Number of subjects: 50
Study 27401709 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary follow‐up visits with clinical examinations, focused chest sonography and protocol‐driven thoracentesis if applicable
Number of subjects: 76
Study 27401709 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracentesis in patients with pleural effusion
Number of subjects: 76
Study 27401709 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 76
Study 25860002 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine BCG vaccination at birth
Number of subjects: 0
Study 25860002 — intervention group
Group type: COMPARATOR
Intervention: Delayed BCG vaccination at 14 weeks
Number of subjects: 0
Study 24171880 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg three times a day for three months
Number of subjects: 60
Study 24171880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21303633 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nostril administration of 25 U insulin
Number of subjects: 8
Study 21303633 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nostril administration of 50 U insulin
Number of subjects: 8
Study 21303633 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nostril administration of 75 U insulin
Number of subjects: 8
Study 21303633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual nostril administration of 50 U insulin
Number of subjects: 8
Study 21303633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual nostril administration of 75 U insulin
Number of subjects: 8
Study 21303633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual nostril administration of 100 U insulin
Number of subjects: 8
Study 21303633 — intervention group
Group type: COMPARATOR
Intervention: Single nostril administration of 25 U insulin with placebo (CPE-215)
Number of subjects: 8
Study 21303633 — intervention group
Group type: COMPARATOR
Intervention: Single nostril administration of 25 U placebo (CPE-215)
Number of subjects: 8
Study 19858237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioline
Number of subjects: 78
Study 19858237 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylcholine
Number of subjects: 78
Study 19858237 — intervention group
Group type: EXPERIMENTAL
Intervention: Trillium
Number of subjects: 78
Study 19858237 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 16884455 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 209
Study 16884455 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1800 mg/day
Number of subjects: 209
Study 16884455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 15541854 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual removal of placenta
Number of subjects: 302
Study 15541854 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous removal of placenta
Number of subjects: 302
Study 11534565 — intervention group
Group type: EXPERIMENTAL
Intervention: Afelimomab (0.3, 1.0, or 3.0 mg/kg)
Number of subjects: 48
Study 11534565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11534565 — intervention group
Group type: EXPERIMENTAL
Intervention: Afelimomab
Number of subjects: 48
Study 9764987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid treatment in primary biliary cirrhosis (9 patients underwent second liver biopsy)
Number of subjects: 37
Study 9764987 — intervention group
Group type: COMPARATOR
Intervention: Primary biliary cirrhosis and primary sclerosing cholangitis
Number of subjects: 37
Study 9764987 — intervention group
Group type: COMPARATOR
Intervention: Controls (7 cases of obstructive jaundice, 10 of hepatitis C virus‐related liver cirrhosis, 14 of chronic hepatitis C, 5 histologically normal liver cases)
Number of subjects: 37
Study 7826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Series of eight photographs showing weights of portions from the 5th to the 95th centile of portion size
Number of subjects: 51
Study 7826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Single photograph of the average (median) portion size
Number of subjects: 51
Study 7826990 — intervention group
Group type: COMPARATOR
Intervention: Average photograph
Number of subjects: 51
Study 7826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographs in colour
Number of subjects: 51
Study 7826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index > or = 30 kg/m2
Number of subjects: 51
Study 3396267 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (n = 13)
Number of subjects: 25
Study 3396267 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 12)
Number of subjects: 25
Study 29378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mass drug administration (MDA) with praziquantel and albendazole before the peak schistosomiasis transmission season
Number of subjects: 200
Study 29378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual MDA after the peak schistosomiasis transmission season
Number of subjects: 200
Study 29378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Two yearly treatments before and after peak schistosomiasis transmission
Number of subjects: 200
Study 29378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual MDA before peak schistosomiasis transmission, coupled with chemical snail control using niclosamide
Number of subjects: 200
Study 27296404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pickled cabbage
Number of subjects: 530
Study 27296404 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli
Number of subjects: 530
Study 27296404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked onion
Number of subjects: 530
Study 27296404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomatoes
Number of subjects: 530
Study 27296404 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw carrot
Number of subjects: 530
Study 27296404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked carrot
Number of subjects: 530
Study 27296404 — intervention group
Group type: EXPERIMENTAL
Intervention: More than three portions of cooked vegetables per week
Number of subjects: 530
Study 27296404 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumption of citrus fruit
Number of subjects: 530
Study 25908311 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised personal training
Number of subjects: 0
Study 25908311 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group training
Number of subjects: 0
Study 25908311 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based smartphone- and health coach-supported training
Number of subjects: 0
Study 23063100 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 1037
Study 23063100 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1037
Study 21646500 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1012
Study 21646500 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1012
Study 21646500 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1012
Study 19537029 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal invasive neurosurgery (MG group)
Number of subjects: 56
Study 19537029 — intervention group
Group type: COMPARATOR
Intervention: Traditional neurosurgery (TG group)
Number of subjects: 56
Study 19537029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 16705349 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive PTK
Number of subjects: 50
Study 15523309 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS score >=10
Number of subjects: 0
Study 15523309 — intervention group
Group type: COMPARATOR
Intervention: QRS score <10
Number of subjects: 0
Study 11503102 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in evidence-based ethics
Number of subjects: 64
Study 9436556 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (300 IU/kg)
Number of subjects: 182
Study 9436556 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (150 IU/kg)
Number of subjects: 182
Study 9436556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 8355436 — intervention group
Group type: EXPERIMENTAL
Intervention: (2'R)-4'-O-tetrahydropyranyladriamycin (THP)
Number of subjects: 21
Study 8355436 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (ADM)
Number of subjects: 21
Study 2904898 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (group A)
Number of subjects: 79
Study 2904898 — intervention group
Group type: EXPERIMENTAL
Intervention: No antibiotic treatment (group B)
Number of subjects: 79
Study 2904898 — intervention group
Group type: COMPARATOR
Intervention: Cerclage (group C)
Number of subjects: 79
Study 2904898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage groups (A and B)
Number of subjects: 79
Study 2904898 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (antibiotic treatment)
Number of subjects: 79
Study 30027499 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided CABG
Number of subjects: 0
Study 30027499 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided CABG
Number of subjects: 0
Study 28199464 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 4631
Study 28199464 — intervention group
Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 4631
Study 26224879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 91
Study 26224879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 23690353 — intervention group
Group type: EXPERIMENTAL
Intervention: CaOH
Number of subjects: 376
Study 23690353 — intervention group
Group type: COMPARATOR
Intervention: MTA
Number of subjects: 376
Study 16648152 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (group D)
Number of subjects: 30
Study 16648152 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (group S)
Number of subjects: 30
Study 16648152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (D and S)
Number of subjects: 30
Study 12830021 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and Exercise Group (DE)
Number of subjects: 77
Study 12830021 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Group (D)
Number of subjects: 77
Study 12830021 — intervention group
Group type: COMPARATOR
Intervention: Control Group (C)
Number of subjects: 77
Study 10203118 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention implemented between 7:00 p.m. and 6:00 a.m. involving feedback to nursing home staff about noise levels and procedures to abate noise and individualize nighttime incontinence care routines
Number of subjects: 267